Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The ABC of clinical and experimental adjuvants--a brief overview.

Literature DB >> 19895847

The ABC of clinical and experimental adjuvants--a brief overview.

Richard Brunner¹, Erika Jensen-Jarolim, Isabella Pali-Schöll.

Abstract

Adjuvants are compounds that can increase and/or modulate the intrinsic immunogenicity of an antigen and elicit strong and long lasting immune responses. During the last 80 years many adjuvants have been used in experimental settings, but due to various shortcomings of most of them only aluminum compounds made it into regular clinical usage. However, during the last years promising candidates have arisen that may finally adjunct or displace aluminum substances as main adjuvant. This review summarizes information on adjuvants currently used in clinical as well as in experimental settings.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19895847 PMCID： PMC2999744 DOI： 10.1016/j.imlet.2009.10.005

Source DB: PubMed Journal: Immunol Lett ISSN： 0165-2478 Impact factor: 3.685

109 in total

Review 1. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.

Authors: Diana Felnerova; Jean-François Viret; Reinhard Glück; Christian Moser
Journal: Curr Opin Biotechnol Date: 2004-12 Impact factor: 9.740

2. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors: Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal: Science Date: 2006-12-22 Impact factor: 47.728

Review 3. The perfect mix: recent progress in adjuvant research.

Authors: Bruno Guy
Journal: Nat Rev Microbiol Date: 2007-07 Impact factor: 60.633

4. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.

Authors: Bethany Hansen; Anna Sokolovska; Harm HogenEsch; Stanley L Hem
Journal: Vaccine Date: 2007-07-16 Impact factor: 3.641

Review 5. Toll-like receptor and RIG-I-like receptor signaling.

Authors: Taro Kawai; Shizuo Akira
Journal: Ann N Y Acad Sci Date: 2008-11 Impact factor: 5.691

6. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.

Authors: Firdausi Qadri; Tanvir Ahmed; Firoz Ahmed; Yasmin Ara Begum; David A Sack; Ann-Mari Svennerholm
Journal: Vaccine Date: 2005-10-10 Impact factor: 3.641

7. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Authors: James W Huleatt; Andrea R Jacobs; Jie Tang; Priyanka Desai; Elizabeth B Kopp; Yan Huang; Langzhou Song; Valerian Nakaar; T J Powell
Journal: Vaccine Date: 2006-08-22 Impact factor: 3.641

8. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Authors: Andreas Wack; Barbara C Baudner; Anne K Hilbert; Ilaria Manini; Sandra Nuti; Simona Tavarini; Hanno Scheffczik; Mildred Ugozzoli; Manmohan Singh; Jina Kazzaz; Emanuele Montomoli; Giuseppe Del Giudice; Rino Rappuoli; Derek T O'Hagan
Journal: Vaccine Date: 2007-12-07 Impact factor: 3.641

9. The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice.

Authors: R Brunner; J Wallmann; K Szalai; P Karagiannis; T Kopp; O Scheiner; E Jensen-Jarolim; I Pali-Schöll
Journal: Clin Exp Allergy Date: 2007-09-10 Impact factor: 5.018

10. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring.

Authors: Isabella Schöll; Ute Ackermann; Cevdet Ozdemir; Nicole Blümer; Tanja Dicke; Serdar Sel; Sarper Sel; Michael Wegmann; Krisztina Szalai; Regina Knittelfelder; Eva Untersmayr; Otto Scheiner; Holger Garn; Erika Jensen-Jarolim; Harald Renz
Journal: FASEB J Date: 2007-01-16 Impact factor: 5.191

37 in total

Review 1. Laser vaccine adjuvants. History, progress, and potential.

Authors: Satoshi Kashiwagi; Timothy Brauns; Jeffrey Gelfand; Mark C Poznansky
Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452

2. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors: Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal: ACS Infect Dis Date: 2019-03-28 Impact factor: 5.084

Review 3. Adjuvants for vaccines to drugs of abuse and addiction.

Authors: Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal: Vaccine Date: 2014-08-08 Impact factor: 3.641

4. Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.

Authors: Pengfei Wang; Dattatray A Devalankar; Qipu Dai; Ping Zhang; Suzanne M Michalek
Journal: J Org Chem Date: 2016-10-13 Impact factor: 4.354

5. Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.

Authors: Zahra Kianmehr; Hoorieh Soleimanjahi; Susan Kaboudanian Ardestani; Fatemeh Fotouhi; Asghar Abdoli
Journal: Med Microbiol Immunol Date: 2014-09-04 Impact factor: 3.402

6. Evaluation of Protective Efficacy of Selected Immunodominant B-Cell Epitopes within Virulent Surface Proteins of Streptococcus pneumoniae.

Authors: Theodora Papastamatiou; John G Routsias; Olga Koutsoni; Eleni Dotsika; Athanassios Tsakris; Vana Spoulou
Journal: Infect Immun Date: 2018-02-20 Impact factor: 3.441

Review 10. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.

Authors: Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal: J R Soc Interface Date: 2013-02 Impact factor: 4.118